Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity of GSK1562902A H5N1 Booster
NCT00652743Phase 3Completed
- Sponsor
- GSK
- Start
- Mar 2008
- Primary completion
- Jun 2011
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 4
01
Overview
Phase 3, open-label trial of Influenza A virus A/Vietnam/1194/2004 (H5N1) antigen (formaldehyde inactivated) in avian influenza (HPAI) (3 arms), sponsored by GSK. Primary endpoints: Haemagglutinin-inhibition (HI) Antibody Concentrations, Seroprotection (SPR) for HI Antibodies and 1 more. Started Mar 2008; status: completed.
02
Drugs
Influenza A virus A/Vietnam/1194/2004 (H5N1) antigen (formaldehyde inactivated)
03
Conditions
avian influenza (HPAI)
Beyond the preview
Go deeper on NCT00652743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00652743.